Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321806 | 0.87 | ALDH1A1 (0.45) | EPHX2ALDH1A1MTORMAPTCCR4 | |
| SCHEMBL4310488 | 0.85 | ALDH1A1 (0.43) | EPHX2ALDH1A1MTORMAPTCCR4 | |
| SCHEMBL4458784 | 0.84 | EPHX2 (0.48) | EPHX2ALDH1A1P2RX7MAPTLMNA | |
| SCHEMBL6224231 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MTORMAPTCCR4NPSR1 | |
| SCHEMBL4321752 | 0.81 | CCR4 (0.42) | ALDH1A1MTORMAPTCCR4 | |
| SCHEMBL4311911 | 0.80 | CYP2D6 (0.39) | EPHX2ALDH1A1MTORMAPT | |
| SCHEMBL4314414 | 0.80 | ALDH1A1 (0.41) | ALDH1A1MTORMAPTCCR4 | |
| SCHEMBL4318911 | 0.80 | ALDH1A1 (0.48) | EPHX2ALDH1A1MTORMAPTLMNA | |
| SCHEMBL4318806 | 0.79 | CCR4 (0.39) | EPHX2ALDH1A1CCR4 | |
| SCHEMBL4321562 | 0.78 | IGF1R (0.41) | EPHX2ALDH1A1MTORMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | EPHX2 4462/4885ALDH1A1 4356/4885MTOR 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.